Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients
Overview
Evaluation of the antipsychotic efficacy and safety of ziprasidone versus olanzapine, risperidone or quetiapine in patients with schizophrenia, schizoaffective and schizophreniform disorders under naturalistic conditions of clinical practice
Full Title of Study: “Tolerability, Safety, And Efficacy Of Ziprasidone (80 – 160 Mg/D) Versus Olanzapine (10 – 20 Mg/D), Risperidone (4 – 8 Mg/D) Or Quetiapine (300 – 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders – A 12-Week Open-Label, Multicenter Clinical Trial.”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
Interventions
- Drug: ziprasidone versus olanzapine , risperidone or quetiapine
- Behavioral: Panss , CGI-C, UKU-SERS-Pa
- Procedure: Blood tests
Clinical Trial Outcome Measures
Primary Measures
- PANSS (The Positive And Negative Syndrome Scale) in a 12 week period
Secondary Measures
- CGI-C score (Clinical Global Impression of Change), UKU-SERS-Pa (Patient self rating version). Safety and tolerability: ECG, serum cholesterol, triglycerides, prolactin, glucose and body weight
Participating in This Clinical Trial
Inclusion Criteria
- Inpatients or outpatients with schizophrenia, schizoaffective and schizophreniform disorders (DSM-IV). – Patients without adequate current treatment (i.e. intolerance to their current treatment or lack of efficacy of current treatment) based on clinical judgement of the investigator Exclusion Criteria:
- A history of intolerance to ziprasidone, olanzapine, risperidone or quetiapine or any of its ingredients
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Pfizer’s Upjohn has merged with Mylan to form Viatris Inc.
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Pfizer CT.gov Call Center, Study Director, Pfizer
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.